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ChemoresistanceGastric neuroendocrine carcinoma (GNEC) is rare cancer detected in the stomach. Previously, we demon-
strated that the poorer prognosis of GNEC patients compared with gastric adenocarcinoma (GAC) patients
was probably due to the lack of response to chemotherapy. Thus, it is crucial to study the specific GNEC
gene expression pattern and investigate chemoresistance mechanism of GNEC. The transcriptome of
GNEC patients was compared with that of GAC patients using RNA-seq. The KEGG analysis was employed
to explore the specific differential expression gene function enrichment pattern. In addition, the tran-
scriptomes of two GNEC cell lines, ECC10 and ECC12, were also compared with those of two GAC cell
lines, MGC-803 and AGS, using RNA-seq. Comparing patient samples and cell lines transcriptome data,
we try to uncover the potential targets and pathways which may affect the chemoresistance of GNEC.
By combing all transcriptome data, we identified 22 key genes that were specifically up-regulated in
GNEC. This panel of genes probably involves in the chemoresistance of GNEC. From our current experi-
mental data, NeuroD1, one of the 22 genes, is associated with the prognosis of GNEC patients.
Knockdown of NeuroD1 enhanced the sensitivity to irinotecan of GNEC cell lines. Our research sheds light
in identifying a panel of novel therapeutic target specifically for GNEC clinical treatment which has not
been reported before.
 2020 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastric neuroendocrine carcinoma (GNEC) is a rare cancer
found in the stomach and accounts for about 4.1% of all neuroen-
docrine tumors [1]. According to ‘‘Trends in the Incidence, Preva-lence, and Survival Outcomes in Patients with Neuroendocrine
Tumors in the United States” and ‘‘Epidemiological trends of pan-
creatic and gastrointestinal neuroendocrine tumors in Japan”, the
incidence of GNEC is increasing in America [2,3]and Japan [4].
The malignancy and prognosis of GNEC are significantly different
from gastric adenocarcinoma (GAC) [5] and most GNEC display
more malignant behaviors [1]. However, little is known about the
typical clinical manifestations or biological and pathological char-
acteristics of GNEC. Currently, two neuroendocrine tumor makers,
CgA (chromogranin A) and SYN (synapsin) are employed for the
diagnosis of GNEC in pathology. In recent years, the treatment of
GNEC has reached an agreement, and it is generally believed that
surgical resection is the most effective treatment for this disease
J Xie, P. Chen, H. Xie et al. Computational and Structural Biotechnology Journal 18 (2020) 2610–2620[6,7]. TNM staging and lymphocyte ratio were reported to predict
the prognosis of GNEC and the levels of CgA and gastrin found to
be danger factors of GNEC in early diagnosis [8–10]. However,
these studies cannot explain the pathogenesis of GNEC. In China,
GNEC patients are often treated as GAC patients with similar
chemotherapeutic drugs including fluorouracil, cisplatin, strepto-
mycin, allium annulus and paclitaxel [11,12]. In our previous
study, we reported that the poorer prognosis of GNEC patients
compared with GAC patients is probably due to the lack of
response to chemotherapy [13]. Therefore, it is important to opti-
mize the chemotherapy strategy for GNEC treatment. For example,
netazepide was reported to slow down GNEC tumor growth and
somatostatin analogue found to have better effect on functional
GNEC but not nonfunctional GNEC [14]. However, so far there have
no studies on the molecular characteristics of GNEC, which will
provide critical insight for developing and identifying more specific
therapeutic targets and more effective chemotherapy strategies.2. Materials and methods
2.1. Cell culture
GNEC cell lines ECC10 and ECC12 were purchased from RIKEN
BRC CELL BANK (Japan). Similar to GAC cell line NUGC, MKN74,
MKN45, KATO III, HGC and MGC-803, GNEC cell line ECC10 and
ECC12 were cultured in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS) while AGS was cultured in DMEM/F12 supple-
mented with 10% FBS (Thermo Scientific). Cells were kept at 37 C
in a humidified incubator with 5% CO2.
2.2. Human specimens for RNA-seq
The resected carcinoma and paired adjacent tissue specimens of
patients were stored in liquid nitrogen, and a fraction of each was
sent for pathology inspection to confirm the diagnosis. The details
of patient information were listed in Table 1. The study was
approved by the ethics committee of Fujian Medical University
Union Hospital (Fujian, China; 2017KY090). Human tissue speci-
mens collected for this study were from residual tissue in blocks
generated for gastrectomy processing. All patients signed informed
consents agreeing on further examinations and investigations. The
tissue specimens were stored in TRIZOL (Invitrogen) and sent to
Sangon Biotech (Shanghai) Co., Ltd for sequencing.
2.3. Immunohistochemistry (IHC)
Tumor specimens of 50 GNEC patient were obtained from
Fujian Medical University Union Hospital (Fujian, China) with
detailed clinic pathologic parameters. All patients underwent gas-
trectomy between 2008 and 2013. The detailed protocol of IHC
staining was followed as previously described. Rabbit anti-
human NeuroD1 antibody was purchased from Proteintech. The
IHC-stained tissue sections were reviewed under a microscope by
two pathologists who were blinded to the clinical parameters
and scored independently according to the intensity of cellular
staining and the proportion of stained tumor cells. In cases of dis-
crepancy, we re-evaluated the samples and consensus scores were
chosen for evaluation. The staining intensity was scored as 0 (no
staining), 1 (weak staining, light yellow), 2 (moderate staining, yel-
low–brown) and 3 (intense staining, brown). The proportion of
stained tumor cells was classified as 0 (5% positive cells), 1 (6%
to 25% positive cells), 2 (26% to 50% positive cells) and 3 (51%
positive cells). The NeuroD1 protein expression was considered
low if the total score (distribution score + intensity score) was 3
or less and high if 4 or more.26112.4. mRNA extraction, RNA-Seq and data analysis
Total RNAs were extracted from tissues and cell samples using
Total RNAExtractor (Trizol) Kit (SangonBiotech) following theman-
ufacturer’s instructions for further RNA-Sequencing. The integrity
andquality of total RNAswere assessed by 1% (w/v) agarose gel elec-
trophoresis and the 260 nm/280 nm absorbance ratio using a Nano-
Drop ND-1000 spectrophotometer. Briefly, mRNA was gathered
usingmagneticbeadswitholigo (dT) and then fragmented into short
fragments, which were prepared as templates to synthesize the
cDNA library. Sequencing of cDNA library was carried out on Illu-
mina HiseqTM using the paired-end technology. Reads were mapped
aligned to the genome assembly Homo sapiens. GRCh38 using
HISAT2andproceeded statistics byRSeQC. The TPMvalueswere cal-
culated for each transcript using StringTie. Differentially expressed
genes (DEGs) were evaluated by taking 2-fold changes, p < 0.05
and q < 0.05 as criteria. Further, Gene Ontology (GO) enrichment
analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway enrichment analyses were performed using DAVID bioin-
formatics resources 6.8 (https://david.ncifcrf.gov/).
2.5. Quantitative reverse transcription PCR (qRT-PCR)
Total RNA extraction from cell lines and qRT-PCR procedure fol-
lowed as previously described [15].GAPDH was used as a loading
control. The primer sequences can be found in Appendix Table S1.
2.6. Establishment of stable cell lines
Lentiviral constructs of NeuroD1-overexpression, NeuroD1-
shRNA and their matched empty vectors were purchased from
Obio Technology (Shanghai) Corp., Ltd. Cells were seeded in 6-
well plate at the concentration of 105 cells per well before len-
tivirus infection. Once the confluence of cells reached around
30%, cells were infected with the lentiviruses at a suitable multi-
plicity using polybrene (10 mg/ml). The cell state was observed
after 6–8 h and the culture media were replaced with fresh media.
After culturing for 48 h, the cells were selected with the corre-
sponding antibiotic puromycin (Sigma). Finally, the cells were har-
vested for mRNA and protein analysis to verify the establishment
of stable cells before expansion.
2.7. Cell proliferation detection
According to different growth characteristics of the cells, ECC10
and ECC12 were planked at a density of 104 cells/well in 96-well
plates while AGS and MGC-803 at a density of 103 cells/well. After
24 h, cells were respectively exposed to gradient concentrations of
5-fluorouracil, cisplatin, irinotecan and oxaliplatin (Sigma-
Aldrich). Cells were sequentially cultivated for 72 h. The cell viabil-
ity was detected using Cell Counting Kit 8 (TransGen Biotech) fol-
lowing the manufacturer’s instructions. The cell proliferation was
detected by Sulforhodamine B (Sigma-Aldrich) as previously
described [16].
2.8. Western blot
Total cellular proteins were extracted in RIPA lysis buffer and
centrifuged at 16,000g, 4 C for 15 min. The protein concentration
was quantified using the BCA kit (Thermo Scientific). Equal
amounts of protein sample were separated on 12% SDS-PAGE gels
and then transferred to nitrocellulose membrane. Membranes
were blocked in 5% skim milk in PBS for 1 h at room temperature,
incubated with primary antibody (anti-NeuoD1, Proteintech
12081-1-AP and anti-actin, Abcam ab115777) overnight at 4 C
and subsequently with its respective secondary antibody at room
Table 1
Characteristics of patients.
Patient ID Age Sex pathology type Tumor stage
T1 65 Male MANEC (40% for large cell type, 60% for adenoacrcinoma) pT3N1M0
T2 60 Female NEC (large cell type) pT3N3M0
T3 75 Female NEC (90% for small cell type, 10% for large cell type) pT3N2M0
T6 65 Male adenocarcinoma (moderately differentiated) pT3N1M0
T7 58 Female adenocarcinoma (poorly differentiated) pT3N3M0
T8 74 Female adenocarcinoma (poorly differentiated) pT3N2M0
MANEC: mixed adenoneuroendocrine carcinoma.
NEC: neuroendocrine carcinoma.
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Odyssey (LI-COR).3. Results
3.1. Transcriptome analysis of the gastric neuroendocrine tumor tissue
RNA-seq analysis was performed using three pairs of GNEC
patient samples that covered all pathological features, including
one pair of mixed adenoneuroendocrine carcinoma (MANEC) that
was intermingled with areas of squamous cell carcinoma or adeno-
carcinoma, each comprising at least 30% of the tumors. An addi-
tional RNA-seq analysis was also performed using three pairs of
matched GAC patient samples to help identify GNEC-specific gene
expression (Table 1). Through tissue transcriptome pattern dis-
tance and cluster analysis, we noticed that the GNEC patient tumorFig. 1. Differential expression analysis and function enrichment of GNEC and GAC. (A) Ge
tumor tissue, GN-T: GNEC tumor tissue, GA-N: GAC non-tumor tissue, GA-T: GAC tumor
(C) Venn diagram to illustrate the overlapped DEGs between GAC samples. (D) The functi
KEGG analysis.
2612tissue samples (GN-T1, GN-T2 and GN-T3) were more similar to
each other compared with other tissue samples (Fig. 1B) including
GNEC non-tumor tissues (GN-N), GAC tumor tissues (GA-T) and
GAC non-tumor tissues (GA-N) (Fig. 1A), suggesting the existence
of GNEC specific gene expression panel. In summary, 3295 genes
were up-regulated, and 151 genes downregulated in the GNEC
tumor samples compared with their adjacent non-tumor tissues
(Fig. 1B). In the three pairs of GAC patient samples, 7346 genes
were up-regulated, and 144 genes downregulated in the GAC
tumor samples compared with their adjacent non-tumor tissues
(Fig. 1C). Further KEGG analysis indicated the specific up-
regulated genes in GNEC patient samples were mainly enriched
in the following pathways: cell cycle, maturity-onset diabetes of
the young, cAMP signaling pathway, non-alcoholic fatty liver dis-
ease, Alzheimer’s disease and glycosaminoglycan biosynthesis
(Fig. 1D). Compared to the GAC enrichment pattern, the GNEC
patient samples displayed specific nerve cell and endocrine cellne expression distance cluster analysis between patient samples (GN-N: GNEC non-
tissue). (B) Venn diagram to illustrate the overlapped DEGs between GNEC samples.
onal enrichment of GNEC and GAC specific dysregulated genes was identified in the
J Xie, P. Chen, H. Xie et al. Computational and Structural Biotechnology Journal 18 (2020) 2610–2620related disease characteristics (maturity onset diabetes of the
young and Alzheimers disease). Still, they shared similar distur-
bance of cell cycle (Fig. 1D).
Meanwhile, we noticed the gene function enrichment pattern of
downregulated genes in GNEC and GAC patient samples were sig-
nificantly different. The specific downregulated genes in GNEC
patient samples were mainly enriched circadian entrainment, glu-
tamatergic synapse, long-term depression, gastric acid secretion
and nicotine addiction (Fig. 1D). Noticeably, we found the abnor-
mal of gastric acid secretion related pathway was in the downreg-
ulated gene enrichment pattern. It had been pointed out that
disorder of gastric acid could lead to GNEC in mice model [17], sup-
porting the validity of our screen.
3.2. Validation of GNEC cell lines and drug sensitivity
To the best of our knowledge, ECC10 and ECC12 were the only
two GNEC cell lines available. From our current observation of
these two cell lines, we noticed that both cell lines are in small cell
type, and grow in grape-like clusters – ‘‘formation of cell clump”
(Fig. 2A). Therefore, to confirm the reliability of these two cell lines,
we first detected the levels of the two GNEC diagnosis makers CgA
and SYN in ECC10 and ECC12. In comparison to GAC cell lines MGC-
803 and AGS, the mRNA levels (Fig. 2B) and protein levels (Fig. 2C)
of CgA and SYN were significantly higher in ECC10 and ECC12,
assuring the validity of these two cell lines for further study.
Firstly, the fold change of the top 6 DEGs from the above RNA-
seq analyses was selected for expression detection in two GNEC
and seven GAC cell lines. And we found that the expression pat-
terns of these targets were correlated with the transcriptome
results of GNEC and GAC tumor samples (Fig. 2D-2I). Next, the
RNA levels of 42 DEGs (26 up-regulated gene and 16 down-
regulated genes) with the most significant fold changes which
were listed after the above 6 targets had been chosen for further
validation in GNEC and GAC cell lines. The GNEC cell lines did
demonstrate a similar unique gene expression pattern as GNEC
patient tissue samples (Appendix Figs. S1 and S2), further confirm-
ing the validity of these two GNEC cell lines. Then in GAC (AGS and
MGC-803) and GNEC (ECC10 and ECC12) cell lines, we tested the
efficacy of chemotherapy drugs commonly used for GNEC patients
including 5-fluorouracil, oxaliplatin, cisplatin and irinotecan. The
two GNEC cell lines displayed lower sensitivity to chemotherapy
drugs than the two GAC cell lines (Fig. 2J, K, L and M), which is con-
sistent with our hypothesis as mentioned earlier that GNEC is more
resistant to chemotherapy drugs.
3.3. Transcriptome analysis of GNEC cell lines
Considering the mixture of cancer cells with other types of cell
such as connective tissues, infiltrated T cells, fibroblasts etc. in
patient samples, we performed another RNA-seq using the two
GNEC cell lines and two GAC cell lines AGS and MGC-803 to
explore further the potential chemoresistance-related pathways
and specific therapeutic targets for GNEC treatment. In total, there
were 2252 up-regulated genes, and 1050 downregulated specific
genes in GNEC cell lines (Fig. 3A). Compared with AGS and MGC-
803, ECC10 and ECC12 contained similar gene expression pattern
(Fig. 3B). The KEGG enrichment analysis showed the up-
regulated genes were significantly enriched in neuroactive signal-
ing and synapse-related pathways (Fig. 3C and D), implying that
GNEC cell lines contained neuron-like characteristics.
To further narrow down the list of GNEC specific DEGs, we com-
pared GNEC patient sample specific DEGs (GNEC versus GAC patient
samples) with GNEC cell line specific DEGs (GNEC versus GAC cell
lines). In total, 304 genes were overlapped (Fig. 4A), and KEGG anal-
ysis showed the overlapped genes were enriched in maturity onset2613diabetes of the young, proximal tubule bicarbonate reclamation,
cAMP signaling pathway and MAPK signaling pathway (Fig. 4B).
These four pathways contain 22 key dysregulated genes out of the
304 genes (Fig. 4C). As expected, these key genes in the respective
enriched pathway clearly differentiate GNEC and GNEC cell lines
from GAC, their adjacent non-tumor tissues and GAC cell lines
(Fig. 1D). Notably, we found the fold change of NeuroD1 level was
themost consistent in the GNEC tumor samples and GNEC cell lines,
comparedwith their adjacent tissue samples, GAC samples and GAC
cell lines. In further protein–protein interaction analysis, we found
that as an important target in maturity onset diabetes of the young
pathway,NeuroD1also associatedwith CACNA1Aenriched inMAPK
signaling pathway (Fig. 5). Therefore, we speculated that NeuroD1
might be the most valuable target for further investigation.
Interestingly, it has been pointed out that in the SN38 (irinote-
can metabolite) resistant HCT116 cell line, CACNA1A served as the
core node in multiple differential genes and signal pathways net-
work, and was likely to mediate irinotecan resistance [18]. More-
over, initial statistical analysis of psychotropic drug effect had
shown that the changes of single nucleotide polymorphisms in
CACNA1A and CACNA1H had a significant correlation with drug
resistance [19]. We indicated that these genes in this network
are likely to be involved in the resistance process of GNEC. There-
fore, we selected NeuroD1 as a representative candidate for this
network to verify whether maturity onset diabetes of the young
pathway or the whole network may affect the chemoresistance.3.4. Knockdown of NeuroD1 accelerated the growth and enhanced the
sensitivity to irinotecan of GNEC cell lines
To evaluate the prognostic roles of NeuroD1 in GNEC, we per-
formed IHC staining of NeuroD1 in 50 pairs of GNEC patient sam-
ples which were collected by our group collected over the past
10 years. In a representative MANEC patient sample, the GNEC
clearly contained higher NeuroD1 protein level compared to GAC
or the non-tumor tissues (Fig. 6A). According to the expression
level of NeuroD1 we defined (Fig. 6B), we found the patients with
lower NeuroD1 level had more prolonged survival (Fig. 6C). It sug-
gested that NeuroD1 may be an important oncogene for GNEC, and
more markers may exist in our gene panel. It was worth noting
that when we used GEPIA database [20] and the Kaplan–Meier
plotter database [21] to characterize the association between Neu-
roD1 expression and prognosis of GAC, we found that in the GEPIA
cohort, the expression of NeuroD1 was not associated with overall
survival of GAC patients (Fig. 6D). Exploration in the Kaplan–Meier
plotter cohort of GAC patients showed similar results that the
expression of NeuroD1 was not associated with overall survival
of GAC patients (Fig. 6E). These results indicated that as a specific
target in GNEC , NeuroD1 possesses significant and specific prog-
nostic value for GNEC but not GAC.
In order to study the functional role of NeuroD1, we stably
knocked down NeuroD1 in GNEC cell lines ECC12 and ECC10
(Fig. 6F and 6G). Based on the cell viability test within four
chemotherapy drugs that we mentioned in Fig. 2J–2M, we found
that under irinotecan treatment, the cell viability of GNEC NeuroD1
knockdown cell lines were significantly lower than the scramble
group respectively (Fig. 6H and 6I). It indicated that NeuroD1
knockdown enhanced the sensitivity of GNEC cell lines to irinote-
can, suggesting the oncogenic function of NeuroD1 may mainly
contribute to the chemoresistance of GNEC cells.4. Discussion
To the best of our knowledge, this is the first systematic tran-
scriptome analysis of GNEC and a serial of dysregulated targets
Fig. 2. GNEC cell lines verification and drug sensitivity detection. (A) ECC10 and ECC12 live cell image. (B) CgA and SYN transcriptional level detection in ECC10 and ECC12 by
PCR. (C) CgA and SYN transcriptional level detection in ECC10 and ECC12 by IHC. (D-I) Validation of RNA-Seq data by quantitative PCR showed 6 selected genes in fold change
top 48. (J-K) Common chemotherapy agents were tested in GNEC and GAC cell lines. Compared to GAC cell lines AGS and MGC-803, GNEC cell lines ECC10 and ECC12 have
lower sensitivity to 5-fluorouracil, oxaliplatin, cisplatin and irinotecan treatment.
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Fig. 3. Differential expression analysis and function enrichment of GNEC and GAC cell lines. (A) Venn diagram to illustrate the overlapped DEGs among the comparison of
ECC10, ECC12, AGS and MGC-803. (B) Gene expression pattern among the comparison of ECC10, ECC12, AGS and MGC-803. (C) The functional enrichment of GNEC cell lines
specific up dysregulated genes were identified in the KEGG analysis. (D) The functional enrichment of GNEC cell lines specific down dysregulated genes were identified in the
KEGG analysis.
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Fig. 4. Differential expression analysis and function enrichment of the comparison of patient samples and cell lines. (A) Venn diagram to illustrate the GNEC patient sample
special DEGs (vs. GAC patient samples DEGs) and GNEC cell lines special DEGs (vs. GAC cell lines DEGs). (B) The functional enrichment of GNEC patient samples and cell lines
specific DEGs was identified in the KEGG analysis. (C) Heatmaps showed Z scores (interpreted as a measure of SD away from the mean) of some selected genes from GNEC
RNA-Seq data. The color scheme was based on the Z scores, red represents up-regulated genes, blue represents downregulated genes and gray represents undetermined
directionality. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
J Xie, P. Chen, H. Xie et al. Computational and Structural Biotechnology Journal 18 (2020) 2610–2620were identified. However, there are several limitations to this
study. First, due to the rarity of GNEC, only three pairs of GNEC
patient samples were finally included for RNA-seq in this study
due to the low GNEC incidence, which may not represent all the
characteristics of GNEC. Second, although we have a frozen GNEC
sample set of over 50 patient samples for IHC and the prognosis
evaluation, all samples were collected in our hospital, and the
number is not very big, thus reducing the reliability of the progno-2616sis analysis. It will be ideal for accumulating more GNEC patient
samples to generate a more detailed dataset of GNEC. But we feel
it is more important to share the discoveries of this first GNEC tran-
scriptome analysis to promote more interest and researches in this
disease.
From RNA-seq analysis, we noticed that there were 3446 co-
dysregulated genes in the comparison of the three pairs of GNEC
patient sample. We found 2423 genes with protein products, 469
Fig. 5. Protein-protein interaction within 22 key dyregulated targets. The analysis was performed by String (https://string-db.org) within these 22 key dyregulated targets
which were enriched in the four specific pathways of overlap part in the Fig. 4A (Each of the colors represents a pathway).
J Xie, P. Chen, H. Xie et al. Computational and Structural Biotechnology Journal 18 (2020) 2610–2620unknown genes and 148 non-coding RNAs. The consistency
between GNEC patient tumor samples is very strong (Fig. 1A).
Notably, compared with GAC, the related KEGG analysis have
shown specific gene function enrichment in GNEC DEGs. Previous
reports indicated that cAMP signaling promotes DNA damage
repair [9] and allows cancer cells to acquire a novel mechanism
that prevents the toxicity of DNA damaging agents [10,11]. Addi-
tionally, the cell cycle is strongly correlated with chemoresistance
and DNA damage repair [12,13]. The enrichment of cAMP and the
cell cycle pathway in GNEC may be one of the reasons why GNEC
patients are more resistant to DNA alkylating agents that lead to
poorer survival.
Based on the significant prognosis difference between GNEC
and GAC, these differential genes may answer the existing
chemoresistance state in GNEC clinical treatment and offer emerg-
ing targets for optimizing GNEC specific chemotherapy strategy.
However, it is hard to avoid that sampling deviation, and potential
immune cell infiltration would affect the accuracy of DEGs result
and further target selection. In order to find out the difference
between GNEC and GAC, we compared GNEC and GAC patient sam-
ple RNA-seq with cell line RNA-seq data, which can help ulteriorly
eliminate the nonspecific DEGs from GNEC patient samples.
Finally, in total, 304 DEGs became our focus. From the KEGG anal-
ysis within these DEGs, we noticed that maturity onset diabetes of
the young, proximal tubule bicarbonate reclamation, cAMP signal-
ing pathway and MAPK signaling pathway were specifically dys-
regulated in GNEC, and maturity onset diabetes of the young
pathway was the most significant one. In further PPI analysis, we
explored the interrelationships among the 22 genes which were
enriched in these four specific pathways (Fig. 5). Based on protein
correlations, we found that compared to proximal tubule bicarbon-
ate reclamation and cAMP signaling pathway, the gene correlation
in maturity onset diabetes of the young pathway and MAPK signal-
ing pathway was closer.
From this PPI analysis, we found that NeuroD1 and CACNA1A
had co-expression relationship. It had been reported that knockout2617of NeuroD1 in murine b-Cell would downregulate the expression
level of CACNA1A [22]. As an essential neuron development related
transcription factor, NeuroD1 is involved in regulating the insulin
secretory process [22]. At the same time, some researches had
pointed out that it was involved in the development of small cell
lung cancer (SCLC) and neuroblastoma [23,24]. Also, we noticed
that in estrogen receptor-negative breast cancers,
high NeuroD1 methylation was more likely to respond with a com-
plete pathologic response following neoadjuvant chemotherapy
[25]. Considering the potential value of maturity onset diabetes
of the young pathway and roles of NeuroD1 in neuron develop-
ment and some NETs, we chose NeuroD1 as a candidate to verify
the GNEC chemoresistance. When we disturbed NeuroD1 expres-
sion, the GNEC cells became more sensitive to irinotecan. In the
future, the related in vivo experiments would be performed to val-
idate the changes of chemosensitivity using GNEC cell line xeno-
graft model.
Meanwhile, in maturity onset diabetes of the young pathway,
absence of NKX2.2 in primary tumor samples of small cell lung
cancer was an independent predictor of improved outcomes in
chemotherapy-treated patients [26]. In the MAPK signaling path-
way, in addition to the related resistance studies of CACNA1Amen-
tioned in the result section, we also noticed in osteosarcoma,
knockdown MAPK8IP1 would enhance the efficacy of doxorubicin
treatment [27]. Moreover, as an important protein in the MAPK
signaling pathway, microtubule-associated protein tau (MAPT)
was involved in cisplatin and paclitaxel resistance mechanisms in
gastric cancer, non-small cell lung cancer, and ovarian cancer
[28–30]. Based on KEGG analysis within GNEC specific DEGs and
related drug resistance studies, we speculate that these 22 genes
included in these four specifically enriched pathways may be
important regulatory factors in the resistance mechanism of GNEC
chemotherapy.
Therefore, we had a reason to believe that this specific panel in
GNEC gene expression pattern was involved in the mechanism of
GNEC chemotherapy drug tolerance. Subsequent research on this
Fig. 6. Evaluation of the prognostic and chemoresisitance roles of NeuroD1 in GNEC. (A) NeuroD1immunohistochemical verification in MANECs. Compared to GAC part, GNEC
part contained high expression level. The top image with 20X magnification is the amplification of the red outlined part in bottom image. (B) Criteria for the degree of gene
expression in immunohistochemical experiment. (C) Comparison of overall survival curves for NeuroD1 low and high expression group in GNEC patients. The expression of
NeuroD1 was not correlated with overall survival in the GEPIA cohort (D) and the Kaplan–Meier plotter cohort (E). (F and G) The knockdown effect of NeuoD1 in GNEC cell
lines. (H and I) Knock down NeuroD1 promoted chemosensitivity of GNEC cell lines to irinotecan (cell viability test), data are presented as mean ± SEM. (For interpretation of
the references to color in this figure legend, the reader is referred to the web version of this article.)
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J Xie, P. Chen, H. Xie et al. Computational and Structural Biotechnology Journal 18 (2020) 2610–2620signal pathway will provide a theoretical basis for GNEC to dis-
cover specific chemoresistance mechanisms and chemotherapy
strategies.5. Conclusions
Compared to the GAC enrichment pattern, the GNEC patient
samples displayed specific nerve cell and endocrine cell related
disease characteristics (maturity onset diabetes of the young and
Alzheimer’s disease), which GNEC showed significant difference
with GAC patient samples. Moreover, cAMP signaling and cell cycle
related pathway existed in KEGG enrichment suggested that GNEC
may contain high DNA damage repair ability and chemoresistance.
Further chemosensitivity detection experiment in vitro showed
GNEC cell lines ECC10 and ECC12 displayed significant chemoresis-
tance ability, compared with GAC cell lines AGS and MGC-803.
Through more RNA-seq analysis, we found the co-regulated genes
from the DEGs of patient samples and cell lines were enriched in
maturity onset diabetes of the young, proximal tubule bicarbonate
reclamation, cAMP signaling pathway and MAPK signaling path-
way. In further exploration, the IHC results indicated that NeuroD1
possesses significant prognosis value for GNEC but not GAC. Then
we found that knockdown of NeuroD1 enhanced the sensitivity
of GNEC cell lines to irinotecan, suggesting the abnormal of these
GNEC specific DEGs enriched in these four pathways may con-
tribute to the chemoresistance of GNEC cells.Declaration of Competing Interest
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